2024 PARTNERS
2024 Partners
Cardiomedex - Innovation Partner
Cardiomedex is a preclinical CRO, highly specialized in cardiovascular and cardiometabolic diseases, that provides reliable preclinical studies using integrative predictive models of HFpEF , HFrEF, cardiac hypertrophy, cardiac fibrosis, myocardial infarction, Ischemia/reperfusion, cardiomyopathy (takotsubo, genetic etc.), cardiometabolic diseases, hypertension, cardiotoxicity, sepsis, etc. and developing new tailor-made models to fulfil our partners’ needs.
Cardiomedex offers ex-vivo (including histology, protein/gene expression, vascular reactivity/isolated heart/cardiomyocytes) and in-vivo exploration (including echocardiography/telemetry/PV loops/electrocardiogram/treadmill/tail cuff) to provide in-depth functional characterization.
Perspectum - Exhibition Partner
Pioneering precision healthcare, Perspectum is leading innovation in non-invasive technology. The company’s track record speaks volumes, having delivered innovative imaging, operational excellence, and protocol consultation services in over 80 commercial trials spanning Phase 0-III in a range of chronic diseases. With a focus on kidney health, our quantitative MRI biomarker suite offers a comprehensive assessment of structural and functional metrics, enabling efficient patient screening and therapeutic efficacy assessment. Experience the future of kidney care with Perspectum's groundbreaking solutions.
SYNCROSOME - Event Partner
SYNCROSOME, an ETAP-Lab company, is a preclinical CRO offering high-level research services for cardiovascular disorders.
At SYNCROSOME we can accelerate, derisk and support your preclinical development thanks to relevant & translatable in vivo modeling of HFrEF, HFpEF, acute myocardial ischemia and arterial/pulmonary arterial hypertension.
Our experts aim to provide our clients with the most relevant data using state-of-the-art techniques and imaging, still to offer better predictability of compounds' efficacy.
ZenSun - Industry Partner
Zensun Sci&Tech: A biotech focused on developing First-in-Class innovative drugs for heart failure. Neucardin - FIC anti-heart failure biologic with a novel target MoA on cardiomyocytes, was granted FDA Fast track designation, and is currently in the U.S./China Phase III clinical stage and is expected to be commercialized in 2025 at the earliest. It has been shown in clinical studies to have the potential to significantly reduce mortality and reverse ventricular remodeling in target patients, now is currently seeking global partners.
